Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation-Reference-Cited by-同舟云学术

Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation

Published:2017-09-18 Issue:FI2 Volume:20 Page:f198-f203
ISSN:1099-5129
Container-title:EP Europace
language:en
Short-container-title:

Author:

Liebregts Max¹,Faber Lothar²,Jensen Morten K³,Vriesendorp Pieter A⁴,Hansen Peter R⁵,Seggewiss Hubert²⁶,Horstkotte Dieter²,Adlova Radka⁷,Michels Michelle⁴,Bundgaard Henning³,ten Berg Jurriën M¹,Veselka Josef⁷

Affiliation:

1. Department of Cardiology, St. Antonius Hospital Nieuwegein, Koekoekslaan 1, EM Nieuwegein, The Netherlands

2. Clinic for Cardiology, Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum, Georgstrasse 11, Bad Oeynhausen, Germany

3. Unit for Inherited Cardiac Diseases, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark

4. Department of Cardiology, Thoraxcenter Erasmus Medical Center, s-Gravendijkwal 230, CE Rotterdam, The Netherlands

5. Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen University Hospital, Kildegardsvej 28, Hellerup, Denmark

6. Department of Internal Medicine, Leopoldina Hospital, Gustav-Adolf-Strasse 8, Schweinfurt, Germany

7. Department of Cardiology, 2nd Medical School, Charles University, University Hospital Motol, V Uvalu 84, Prague, Czech Republic

Publisher

Oxford University Press (OUP)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/europace/article-pdf/20/FI2/f198/25734788/eux251.pdf

Reference15 articles.

1. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC);Elliott;Eur Heart J,2014

2. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines;Maron;J Am Coll Cardiol,2003

3. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Gersh;Circulation,2011

4. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithm for sudden cardiac death in patients with hypertrophic cardiomyopathy;O’Mahony;Heart,2013

5. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD);O’Mahony;Eur Heart J,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trans-Atlantic Differences in Approach to Sudden Death Prevention in Patients With Hypertrophic Cardiomyopathy;Canadian Journal of Cardiology;2024-05

2. The challenge of risk stratification in hypertrophic cardiomyopathy: Clinical, genetic and imaging insights from a quaternary referral centre;International Journal of Cardiology;2024-01

3. Outcomes of Alcohol Septal Ablation in Patients With Severe Left Ventricular Outflow Tract Obstruction: A Propensity Score Matching Analysis;Canadian Journal of Cardiology;2023-11

4. Invasive therapies for symptomatic obstructive hypertrophic cardiomyopathy;Progress in Cardiovascular Diseases;2023-09

5. Looking Back at 30 Years of Alcohol Septal Ablation and Looking Forward to the Future;Canadian Journal of Cardiology;2023-09